ABBV vs JNJ: AbbVie vs Johnson & Johnson Stock Comparison: AI Score, Valuation, Performance and Upside
AbbVie is a focused pharmaceutical company executing on a clear post-Humira transition with Skyrizi and Rinvoq, plus the Allergan aesthetics franchise; Johnson & Johnson is a diversified healthcare company spanning innovative pharmaceuticals and a large MedTech business. AbbVie offers a higher dividend yield and a clearer near-term growth narrative; JNJ offers more business diversification and MedTech exposure.
Use this ABBV vs JNJ comparison to choose between a high-yield focused pharma compounder and a diversified healthcare quality franchise. AbbVie's Skyrizi/Rinvoq transition is the clearest near-term driver; JNJ's value lies in the combination of its pharma pipeline and MedTech robotic surgery growth.
ABBV holds the edge across 3 of 5 key metrics in this comparison. JNJ has delivered stronger 1-year price return (+54.39% vs +37.31%), though ABBV has the better forward P/E setup (15.63x vs 19.73x for JNJ). ABBV leads on both revenue growth (12.40%) and operating margin (32.16%), suggesting a stronger fundamental setup on both dimensions. Analyst consensus implies similar upside for both: +4.75% for ABBV and +6.68% for JNJ.
- →Want a high-dividend-yield pharmaceutical compounder with a clear post-Humira growth transition
- →Value Skyrizi and Rinvoq as proven blockbusters continuing to grow faster than Humira declines
- →Like the Botox/Allergan franchise as a durable aesthetics and therapeutics revenue stream
- →Prefer a more focused pharmaceutical holding without the MedTech complexity of JNJ
- →Want diversified healthcare exposure spanning both innovative pharmaceuticals and MedTech devices
- →Value Darzalex's oncology growth and Ottava robotic surgery as distinct long-term catalysts
- →Prefer a lower-yield but more durable Dividend King with 60+ consecutive years of dividend growth
- →Seek a more defensive healthcare holding with two business segments that partially offset each other cyclically
| Metric | ABBV | JNJ |
|---|---|---|
| AI score | 49.8 | 43.1 |
| AI rank | #521 | #874 |
| Latest close | $256.92 | $259.27 |
| 1M return | +9.44% | +8.44% |
| 6M return | +18.86% | +18.93% |
| 1Y return | +37.31% | +54.39% |
How much would $10,000 be worth today if invested at the start of each period, with all dividends reinvested?
| Period | ABBV | JNJ |
|---|---|---|
| 1Y ago | $13.48K (+34.8%) started 2025-07-23 | $15.33K (+53.3%) started 2025-07-23 |
| 5Y ago | $29.43K (+194.3%) started 2021-07-26 | $18.8K (+88.0%) started 2021-07-26 |
| 10Y ago | $90.53K (+805.3%) started 2016-07-25 | $34.61K (+246.1%) started 2016-07-25 |
Hypothetical — past performance does not guarantee future results.
| Metric | ABBV | JNJ |
|---|---|---|
| Market cap | $449.63B | $609.12B |
| Trailing P/E | 124.75 | 29.32 |
| Forward P/E | 15.63 | 19.73 |
| Price/Sales | 5.85 | 4.18 |
| EV/Revenue | 8.17 | 6.56 |
| Analyst target | $266.57 | $269.95 |
| Target upside | +4.75% | +6.68% |
| Metric | ABBV | JNJ |
|---|---|---|
| Revenue growth | 12.40% | 6.60% |
| Earnings growth | -46.20% | -1.00% |
| EPS growth | -46.20% | -1.00% |
| FCF margin | +33.13% | +12.78% |
| Operating margin | 32.16% | 28.61% |
| Profit margin | 5.79% | 21.48% |
| ROIC proxy | 6225.00% | 26.42% |
| Return on equity | 6225.00% | 26.42% |
| Dividend yield | 2.72% | 2.12% |
| Beta | 0.28 | 0.23 |
| Debt/equity | 4789.60 | 67.73 |
| Current ratio | 0.80 | 1.02 |
| Quick ratio | 0.52 | 0.69 |
Lower drawdown and smaller single-period drops generally indicate a smoother ride, though they do not guarantee lower future risk.
| Period | Metric | ABBV | JNJ |
|---|---|---|---|
| 1Y | Growth | +34.83% | +53.32% |
| CAGR | +34.89% | +53.42% | |
| Sharpe ratio | 1.11 | 2.21 | |
| Max drawdown | 19.23% | 10.96% | |
| Max daily drop | 5.20% | 2.69% | |
| Max wkly drop | 8.49% | 6.22% | |
| 5Y | Growth | +151.99% | +67.96% |
| CAGR | +20.34% | +10.95% | |
| Sharpe ratio | 0.72 | 0.43 | |
| Max drawdown | 21.92% | 18.41% | |
| Max daily drop | 12.57% | 7.59% | |
| Max wkly drop | 17.30% | 9.18% | |
| 10Y | Growth | +479.03% | +164.02% |
| CAGR | +19.21% | +10.20% | |
| Sharpe ratio | 0.64 | 0.37 | |
| Max drawdown | 45.09% | 27.37% | |
| Max daily drop | 16.25% | 10.04% | |
| Max wkly drop | 19.39% | 13.25% |
| Category | ABBV | JNJ |
|---|---|---|
| Company | AbbVie Inc. | Johnson & Johnson |
| Sector | Healthcare | Healthcare |
| Industry | Drug Manufacturers - General | Drug Manufacturers - General |
| Core business | Large-cap pharmaceutical company. Core immunology drugs include Skyrizi (risankizumab) and Rinvoq (upadacitinib), which are replacing Humira as the revenue drivers. Also markets Botox (aesthetics and therapeutics), Vraylar (psychiatry), and Venclexta (oncology) through the Allergan acquisition. | Diversified healthcare company split into Innovative Medicine (pharmaceuticals) and MedTech (surgical robotics, orthopedics, cardiovascular, vision). Kenvue (consumer health) was spun off in 2023. Core drugs include Darzalex, Tremfya, Erleada, and Carvykti. |
| Investor focus | Skyrizi and Rinvoq revenue trajectory replacing Humira erosion, Allergan aesthetics recovery, psychiatry pipeline, and dividend sustainability. | Innovative Medicine pipeline productivity, MedTech robotic surgery growth, Darzalex and Tremfya as post-Stelara growth anchors, talc litigation resolution, and dividend growth. |
- →Skyrizi and Rinvoq are both growing rapidly and are expected to generate more combined revenue than Humira at peak
- →Allergan acquisition adds Botox franchise — a durable, aesthetics-and-neurology revenue stream
- →One of the highest dividend yields in large-cap pharmaceuticals, with a track record of consistent growth
- →Two distinct high-quality businesses in one holding — Innovative Medicine and MedTech both operate at scale
- →Darzalex (multiple myeloma) is one of the fastest-growing large-cap pharma drugs and has multiple new indication opportunities
- →MedTech Ottava robotic surgery system represents a significant new growth platform if commercially validated
- →Humira biosimilar erosion is ongoing — revenue from the world's former best-selling drug continues to decline
- →Skyrizi and Rinvoq must sustain strong growth to fully offset Humira losses — execution is critical
- →High debt from the Allergan acquisition, though being progressively paid down from strong cash flows
- →Talc litigation overhang — ongoing legal proceedings related to baby powder asbestos claims create headline risk
- →Stelara (psoriasis/IBD) facing biosimilar competition — this blockbuster drug is in revenue decline
- →MedTech competitive dynamics in robotic surgery (Intuitive Surgical's dominant position is hard to dislodge)
Want deeper AI forecasts?
This comparison page is public and free forever. Subscribers can unlock saved watchlists, full AI rankings, detailed forecasts, and interactive analysis tools.